Nangaku M[au] - Search Results

Year	Number of Results
1990	3
1991	2
1992	1
1994	1
1995	1
1996	4
1997	7
1998	8
1999	6
2000	1
2001	7
2002	14
2003	13
2004	16
2005	18
2006	15
2007	23
2008	22
2009	8
2010	12
2011	10
2012	14
2013	31
2014	42
2015	37
2016	30
2017	36
2018	42
2019	67
2020	87
2021	80
2022	9

1

Treatment of Diabetic Kidney Disease: Current and Future.

Yamazaki T, Mimura I, Tanaka T, Nangaku M. Yamazaki T, et al. Among authors: nangaku m. Diabetes Metab J. 2021 Jan;45(1):11-26. doi: 10.4093/dmj.2020.0217. Epub 2021 Jan 22. Diabetes Metab J. 2021. PMID: 33508907 Free PMC article. Review.

2

Mitochondrial Damage Causes Inflammation via cGAS-STING Signaling in Acute Kidney Injury.

Maekawa H, Inoue T, Ouchi H, Jao TM, Inoue R, Nishi H, Fujii R, Ishidate F, Tanaka T, Tanaka Y, Hirokawa N, Nangaku M, Inagi R. Maekawa H, et al. Among authors: nangaku m. Cell Rep. 2019 Oct 29;29(5):1261-1273.e6. doi: 10.1016/j.celrep.2019.09.050. Cell Rep. 2019. PMID: 31665638 Free article.

3

Pathogenesis of Atypical Hemolytic Uremic Syndrome.

Yoshida Y, Kato H, Ikeda Y, Nangaku M. Yoshida Y, et al. Among authors: nangaku m. J Atheroscler Thromb. 2019 Feb 1;26(2):99-110. doi: 10.5551/jat.RV17026. Epub 2018 Nov 2. J Atheroscler Thromb. 2019. PMID: 30393246 Free PMC article. Review.

4

Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors.

Yap DYH, McMahon LP, Hao CM, Hu N, Okada H, Suzuki Y, Kim SG, Lim SK, Vareesangthip K, Hung CC, Nangaku M; APSN HIF-PHI Recommendation Committee. Yap DYH, et al. Among authors: nangaku m. Nephrology (Carlton). 2021 Feb;26(2):105-118. doi: 10.1111/nep.13835. Epub 2020 Dec 9. Nephrology (Carlton). 2021. PMID: 33222343 Free PMC article. Review.

5

Update on diagnosis, pathophysiology, and management of diabetic kidney disease.

Sugahara M, Pak WLW, Tanaka T, Tang SCW, Nangaku M. Sugahara M, et al. Among authors: nangaku m. Nephrology (Carlton). 2021 Jun;26(6):491-500. doi: 10.1111/nep.13860. Epub 2021 Feb 17. Nephrology (Carlton). 2021. PMID: 33550672 Review.

6

COVID-19 of dialysis patients in Japan: Current status and guidance on preventive measures.

COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians; Japanese Society for Dialysis Therapy; Japanese Society of Nephrology, Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Hanafusa N, Sakai K, Kanno Y, Ando R, Shinoda T, Nakamoto H, Akizawa T. COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, et al. Among authors: nangaku m. Ther Apher Dial. 2020 Aug;24(4):361-365. doi: 10.1111/1744-9987.13531. Ther Apher Dial. 2020. PMID: 32506762 Free PMC article. Review.

7

Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease.

Ishii T, Tanaka T, Nangaku M. Ishii T, et al. Among authors: nangaku m. Ther Clin Risk Manag. 2021 Feb 17;17:155-163. doi: 10.2147/TCRM.S293879. eCollection 2021. Ther Clin Risk Manag. 2021. PMID: 33628028 Free PMC article. Review.

8

More reasons to use SGLT2 inhibitors: EMPEROR-reduced and DAPA-CKD.

Nangaku M. Nangaku M. Kidney Int. 2020 Dec;98(6):1387-1389. doi: 10.1016/j.kint.2020.10.002. Epub 2020 Oct 14. Kidney Int. 2020. PMID: 33068607 No abstract available.

9

Preface.

Nangaku M, Silva Junior G. Nangaku M, et al. Contrib Nephrol. 2021;199:VII-VIII. doi: 10.1159/000517715. Epub 2021 Jul 27. Contrib Nephrol. 2021. PMID: 34315163 No abstract available.

10

Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes.

Ueki K, Sasako T, Okazaki Y, Miyake K, Nangaku M, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. Ueki K, et al. Among authors: nangaku m. Kidney Int. 2021 Jan;99(1):256-266. doi: 10.1016/j.kint.2020.08.012. Epub 2020 Sep 4. Kidney Int. 2021. PMID: 32891604 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results